Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for ...
June 08 2020 - 3:02PM
- Company to provide updates on the initiation of human
trials for treatment of adult hospitalized patients with
COVID-19
- Phase II clinical trial will be conducted with
merimepodib and remdesivir in multiple sites nationwide with
data expected in the third quarter 2020
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the
“Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc.,
today announced a reminder that it will host a call to discuss the
Phase II clinical trials of merimepodib, its broad-spectrum oral
anti-viral candidate for the treatment of COVID-19 in adult
patients.
The format will be a management presentation updating recent
developments followed by a Q&A session with select call
attendees.
Conference Call Details:
Date: Tuesday, June 9, 2020Time: 11:00 AM Eastern Time (ET)Dial
in Number for U.S. Callers: 1-877-407-8293Dial in Number for
International Callers: 1-201-689-8349
A replay will be available for two weeks starting on June 9,
2020 at approximately 2:00 PM ET. To access the replay, please dial
1-877-660-6853 in the U.S. and 1-201-612-7415 for international
callers. The conference ID# is 13704617.
On May 14, 2020, an article titled, "The IMPDH inhibitor
merimepodib provided in combination with the adenosine analogue
remdesivir reduces SARS-CoV-2 replication to undetectable levels in
vitro" was published by F1000 Research, an online peer-reviewed
life sciences journal publishing program in biology and medicine.
The article cites that merimepodib in combination with remdesivir
decreases viral production of SARS-CoV-2 to undetectable levels in
pre-clinical testing.
On May 18, 2020, ViralClear announced the FDA’s clearance of its
IND to proceed with a proposed Phase II study of merimepodib in
COVID-19 patients. The human clinical trial is planned to be
conducted under the leadership of Dr. Andrew D. Badley, Professor
and Chair of the Department of Molecular Medicine and the
Enterprise Chair of the COVID-19 Task Force at Mayo Clinic.
On June 5, 2020, ViralClear announced that it has expanded its
patient enrollment centers to include St. David’s South Austin
Medical Center in Austin, TX. The hospital is part of St. David’s
HealthCare, one of the largest healthcare systems in Texas. The
Company intends to commence its Phase II clinical trial for
merimepodib, its broad-spectrum oral anti-viral candidate for the
treatment of COVID-19 in adult patients in the coming weeks.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About Viral Clear Pharmaceuticals and Merimepodib
(MMPD)BioSig’s subsidiary, ViralClear
Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical
called merimepodib to treat patients with COVID-19. Merimepodib is
intended to be orally administered, and has demonstrated
broad-spectrum in vitro antiviral activity, including strong
activity against SARS-CoV-2 in cell cultures. Merimepodib was
previously in development as a treatment for chronic hepatitis C
and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with
12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400
subjects and patients and an extensive preclinical safety package
was completed. A manuscript titled, “The IMPDH inhibitor
merimepodib provided in combination with the adenosine analogue
remdesivir reduces SARS-CoV-2 replication to undetectable levels in
vitro”, was submitted to an online peer-reviewed life sciences
journal. This manuscript is authored by Natalya Bukreyeva, Rachel
A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and
Slobodan Paessler of the UTMB Galveston National Laboratory and Dr.
Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as
a corresponding author. This article highlights pre-clinical data
generated under contract with Galveston National Laboratory at The
University of Texas Medical Branch.
Forward-looking StatementsThis press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024